| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/10/2003 | US20030129596 Chemical compounds |
| 07/10/2003 | US20030129579 Multi-use multimodal imaging chelates |
| 07/10/2003 | US20030129295 Comprises protective lipid coating (hydrogenated oils) for choline chloride or lysine hydrochloride; ruminant feeds |
| 07/10/2003 | US20030129294 Hydroquinone-substituted fatty acid for use in foods; lipase inhibitors; peroxisome proliferator activated receptors; antiaging agents |
| 07/10/2003 | US20030129278 Oligosaccharide mixture |
| 07/10/2003 | US20030129268 Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dematology, in cosmetics and as food additive |
| 07/10/2003 | US20030129266 Interleukin-4 production inhibitors |
| 07/10/2003 | US20030129265 Interleukin-4 production inhibitors |
| 07/10/2003 | US20030129261 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 07/10/2003 | US20030129254 Bactericidal/disinfectant peracetic and acid composition |
| 07/10/2003 | US20030129250 Particulate compositions for improving solubility of poorly soluble agents |
| 07/10/2003 | US20030129249 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
| 07/10/2003 | US20030129246 Process for preparing solid dosage forms of very low-dose drugs |
| 07/10/2003 | US20030129245 Mixing micronised formoterol its salt or solvate with a pre-micronised carrier/diluent at low energy, agglomerating and spheronisation or adding a coarse carrier/diluent; treating respiratory system disorders |
| 07/10/2003 | US20030129244 Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations |
| 07/10/2003 | US20030129242 Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| 07/10/2003 | US20030129241 Effective amount of a vasoactive prostaglandin, a polysaccharide thickener, a lipophilic component, and an acidic buffer system |
| 07/10/2003 | US20030129240 Polyoxyalkylene block copolymer at desired concentrations with or without a therapeutic agent |
| 07/10/2003 | US20030129237 Multiparticulate modified release composition |
| 07/10/2003 | US20030129235 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 07/10/2003 | US20030129234 Methods of making sustained release formulations of oxymorphone |
| 07/10/2003 | US20030129231 Carrier causes oxycodone hydrochloride to preferentially release the drug in gastric fluid; analgesics |
| 07/10/2003 | US20030129230 Sustained release formulations of oxymorphone |
| 07/10/2003 | US20030129229 Pulse dosage formulations of methylphenidate and method to prepare same |
| 07/10/2003 | US20030129227 Beta-lactam antibiotic-containing tablet and production thereof |
| 07/10/2003 | US20030129221 A mixture of lipids containing a protonatable or deprotonatable lipid, such as polyoxyethylene glycol or polyamide oligomer modified lipid, or amino lipid is combined with a buffered aqueous solution of a charged drug |
| 07/10/2003 | US20030129220 Transdermal administration of androgenic drugs using hydroxide-releasing agents as permeation enhancers |
| 07/10/2003 | US20030129217 Hypocholesterolemic composition and methods of use |
| 07/10/2003 | US20030129216 A kit containing the enzyme lipoprotein lipase in a stabilized form in a container and a topical formulation of monoglycerides, diglycerides or triglycerides of synthetic, plant or animal origin for application to human skin |
| 07/10/2003 | US20030129209 Topical application of cetirizine and loratadine |
| 07/10/2003 | US20030129208 Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses |
| 07/10/2003 | US20030129202 Mutated hepatitis b virus, its nucleic and protein constituents and uses thereof |
| 07/10/2003 | US20030129189 Angiogenesis inhibitors for treament of inflammation, cachexia, septic shock, cerebral malaria, arthritis, and graft-rejection |
| 07/10/2003 | US20030129182 Contacting vitreous humor with beta-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase, and/or protein kinase; thimerosal-free |
| 07/10/2003 | US20030129179 Memory enhancing protein |
| 07/10/2003 | US20030129177 Mixture of carnitine compound, coenzyme Q10, nicotinamide, riboflavin and pantothenic acid; cardiovascular disorders |
| 07/10/2003 | US20030129171 Cloning mastitis gene; muscular disorders |
| 07/10/2003 | US20030129167 Enhanced production of blood components, blood cells and plasma without freezing |
| 07/10/2003 | US20030129158 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions |
| 07/10/2003 | US20030129157 Glycoglyceride; applying hair, skin, lips |
| 07/10/2003 | US20030129145 Aftersmoking; converting nicotine to cotinine; discharing in urine |
| 07/10/2003 | US20030129141 Dispersable dry powder; controlling moisture concentration, particle size; in situ drug delivery |
| 07/10/2003 | US20030129140 In situ infection therapy; aminoglycoside antibiotics |
| 07/10/2003 | US20030129134 Method of monitoring neuroprotective treatment |
| 07/10/2003 | US20030127621 Kinesin motor modulators derived from the marine sponge adocia |
| 07/10/2003 | CA2503801A1 2-substituted vitamin d derivatives |
| 07/10/2003 | CA2482392A1 Carboxylic acid derivative |
| 07/10/2003 | CA2472121A1 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof |
| 07/10/2003 | CA2471910A1 Benzocyclodecane derivatives with antitumor activity |
| 07/10/2003 | CA2471903A1 Micronized pharmaceutical or nutraceutical powder with immediate release |
| 07/10/2003 | CA2471713A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors |
| 07/10/2003 | CA2471679A1 Negatively charged polysaccharide derivable from aloe vera |
| 07/10/2003 | CA2471635A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 07/10/2003 | CA2471531A1 Agents for treating mild cognitive impairment |
| 07/10/2003 | CA2471385A1 Preventives/remedies for cancer |
| 07/10/2003 | CA2471348A1 Quinazolinone derivative |
| 07/10/2003 | CA2471306A1 Secreted proteins |
| 07/10/2003 | CA2471300A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std) |
| 07/10/2003 | CA2471297A1 Human netrin receptor and uses thereof |
| 07/10/2003 | CA2471236A1 Urea derivatives |
| 07/10/2003 | CA2471217A1 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same |
| 07/10/2003 | CA2471130A1 Il-17 like molecules and uses thereof |
| 07/10/2003 | CA2471049A1 Amide derivatives as gk activators |
| 07/10/2003 | CA2471039A1 Method of systemically delivering ssris |
| 07/10/2003 | CA2470903A1 A system for stable expression of sirnas in mammalian cells |
| 07/10/2003 | CA2470696A1 Pecam-1 modulation |
| 07/10/2003 | CA2470666A1 Secreted protein |
| 07/10/2003 | CA2470521A1 Anti-viral 7-deaza l-nucleosides |
| 07/10/2003 | CA2470367A1 Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis |
| 07/10/2003 | CA2469967A1 Urea derivatives as vr1- antagonists |
| 07/10/2003 | CA2469690A1 Beta-amyloid binding factors and inhibitors thereof |
| 07/10/2003 | CA2467337A1 Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
| 07/10/2003 | CA2464937A1 Long chain fatty alcohol substituents in antineoplastic agents |
| 07/10/2003 | CA2463738A1 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 07/10/2003 | CA2457801A1 Streptococcus thermophilus strain and use thereof |
| 07/09/2003 | EP1325929A2 Cytotoxic cyplasin of the sea hare, Aplysia punctata, cDNA cloning and expression of bioreactive recombinants |
| 07/09/2003 | EP1325922A2 Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity |
| 07/09/2003 | EP1325921A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators |
| 07/09/2003 | EP1325920A1 N-substituted benzothiophenesulfonamide derivatives |
| 07/09/2003 | EP1325918A1 Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases |
| 07/09/2003 | EP1325917A1 Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands |
| 07/09/2003 | EP1325916A1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system |
| 07/09/2003 | EP1325915A1 Monomeric and dimeric naphtylisoquinoline alkaloids and synthesis methods thereof |
| 07/09/2003 | EP1325914A1 Tetrahydroquinoline compounds |
| 07/09/2003 | EP1325908A1 Process for the preparation of an enantiomerically enriched thio compound |
| 07/09/2003 | EP1325765A1 Combinations of Formoterol and Mometasone Furoate for Asthma |
| 07/09/2003 | EP1325757A1 Embolic materials |
| 07/09/2003 | EP1325753A2 Bio-compatible means for controlled drug delivery to tissue and method of use |
| 07/09/2003 | EP1325748A1 Preventive or therapeutic drugs for cancers containing cyanidin compounds as the active ingredient |
| 07/09/2003 | EP1325747A2 Dietary supplement for neuropaths |
| 07/09/2003 | EP1325746A1 Controlled release oxycodone compositions |
| 07/09/2003 | EP1325745A1 Preventives and remedies for complications of diabetes |
| 07/09/2003 | EP1325744A1 Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof |
| 07/09/2003 | EP1325743A1 Compositions for improving lipid metabolism |
| 07/09/2003 | EP1325742A1 Improved transdermal therapeutic system for the treatment of Parkinson's disease |
| 07/09/2003 | EP1325740A1 Stable granulates containing S-Adenosylmethionine and process for the preparation thereof |
| 07/09/2003 | EP1325734A1 Process for the preparation of ozone and peroxide derivatives of fatty acids or their esters in the form of a spreadable ointment |
| 07/09/2003 | EP1325681A1 Composition for promotion of bone growth and maintenance of bone health |
| 07/09/2003 | EP1325341A2 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 07/09/2003 | EP1325338A2 Diagnosis and treatment of alzheimer's disease |